- Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients
- Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
- Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
- Newron Presents 2023 Financial Results and Provides 2024 Outlook
- Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
More ▼
Key statistics
On Friday, Newron Pharmaceuticals SpA (NWRN:SWX) closed at 10.60, -7.42% below its 52-week high of 11.45, set on Jan 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.40 |
---|---|
High | 10.78 |
Low | 10.26 |
Bid | 10.30 |
Offer | 10.70 |
Previous close | 10.44 |
Average volume | 231.70k |
---|---|
Shares outstanding | 18.63m |
Free float | 17.07m |
P/E (TTM) | -- |
Market cap | 195.07m CHF |
EPS (TTM) | -0.895 CHF |
Data delayed at least 15 minutes, as of May 17 2024 16:30 BST.
More ▼